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Background: Although a lower methylation level of whole genome has been demonstrated in Tetralogy of Fallot
(TOF) patients, little is known regarding changes in specific gene DNA methylation profiles and the possible
associations with TOF. In current study, the promoter methylation statuses of congenital heart defect (CHD)
candidate genes were measured in order to further understand epigenetic mechanisms that may play a role in the
development of TOF.
Methods: The methylation levels of CHD candidate genes were measured using the Sequenom MassARRAY
platform. QRT-PCR was used to analyze the mRNA levels of CHD candidate genes in the right ventricular
myocardium of TOF cases and normal controls.
Results: Methylation status analysis was performed on the promoter regions of 71 CHD candidate genes (113
amplicons). We found significant differences in methylation status, between TOF cases and controls, in 26
amplicons (26 genes) (p < 0.05). Of the 26 amplicons, 17 were up regulated and 9 were down regulated.
Additionally, 14 of them were located in the CpG islands, 7 were located in the CpG island shores, and 5 were
covering the regions near the transcription start site (TSS). The methylation status was subsequently confirmed and mRNA
levels were measured for 7 represented candidate genes, including EGFR, EVC2, NFATC2, NR2F2, TBX5, CFC1B and GJA5. The
methylation values of EGFR, EVC2, TBX5 and CFC1B were significantly correlated with their mRNA levels (p < 0.05).
Conclusions: Aberrant promoter methylation statuses of CHD candidate genes presented in TOF cases may contribute to
the TOF development and have potential prognostic and therapeutic significance for TOF disease.
Keywords: DNA methylation, Congenital heart defect candidate genes, Tetralogy of FallotBackground
A congenital heart defect (CHD) is an abnormality in the
structure and great vessels of the heart, which is present at
birth. About 19–75 people per 1000 are born with CHD
each year, depending on which types of defects are included
[1] and the incidence is higher if stillbirths were included
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stated.congenital heart disease [3], accounting for 10% of all con-
genital heart diseases [4]. The four distinct anatomical fea-
tures that characterize TOF are pulmonary outflow tract
obstruction, ventricular septal defect, overriding aortic root
and right ventricular hypertrophy [5]. TOF is considered to
be a neural crest cell and/or second heart field related con-
otruncal heart defects that occur during embryonic devel-
opment [6]. Although advances in surgical techniques,
cardiopulmonary bypass and postoperative care in the last
few decades have brought us today to where survival after
complete repair is greater than 98% in large congenital
heart surgery programs [7] and have improved the life qual-
ity of TOF patients to an excellent condition, late sudden
cardiac death remains a persistent risk, with an estimatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Anagraphical characteristics of TOF cases and
normal controls
Characteristic TOF (N = 41)
(months)
Control (N = 6)
(months)
Age [median (IQR)] 11.0 (7.0 – 24.0 ) 15.0 (10.5 – 30.0)
Gender
Male (%) 26 ( 63.4 ) 4 ( 66.7 )
Female (%) 15 ( 36.6 ) 2 ( 33.3 )
IQR, Interquartile range.
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TOF remains unclear. Some studies have reported that
some of these defects related to TOF may be associated
with chromosomal aneuploidy, including trisomies 13, 18
and 21 [9]. In addition to chromosomal rearrangements,
mutations in a number of genes have also been found to be
associated with TOF. A variety of gene insertion/deletion
has been detected in patients with TOF. These genes
include JAG1 [10,11], NKX2-5 and GATA4 [12,13] etc.
However, a single gene mutation or deletion can be identi-
fied only in a small percentage of cases [14]. Thus, we
hypothesize that aberrant epigenetic regulation may be an-
other important factor associated with TOF. Epigenetics re-
fers to the heritable changes in genome function that occur
without a change in the primary DNA sequence. These are
characterized by covalent modifications of cytosine bases
and histones, and changes in the positioning of nucleo-
somes [15]. Currently, the most widely studied epigenetic
modification in humans is DNA methylation. DNA methy-
lation can control the transcriptional activity of genes by
various mechanisms, which occurs almost exclusively in
the context of CpG dinucleotides [16]. The CpG dinucleo-
tides tend to cluster in regions called CpG islands. Studies
have proven that over 60% of human gene promoters are
overlapped with CpG islands and are usually unmethylated
in normal cells [17]. However, recent work on colon cancer
has demonstrated that DNA methylation not only occurs at
CpG islands, but also takes place in regions of lower CpG
density that lie in close proximity (~2 kb) to the CpG
islands, which is known as the CpG island shore [18]. The
CpG island shores are the most enriched with functional
CpG sites and have variable methylation, which are closely
associated with transcriptional regulation. Most of the
tissue-specific DNA methylation seems to occur, not at
CpG islands, but at CpG island shores [19,20].
Methylation within gene promoters and CpG-dense
sequences (CpG islands) have the highest functional
relevance to gene expression control and the aberrant
methylation changes contribute to many diseases [15]. The
methylation patterns of multiple genes can provide differ-
ent types of useful information about cancer cells [21].
The CpG island methylator phenotype, referring to the
concurrent methylation of multiple genes, is a useful
marker for tumor progression and has been reported in
hepatocellular carcinoma [22]. However, although a lower
methylation level of global genome has been demonstrated
in TOF patients [23], little is known about gene-specific
DNA methylation changes in patients with TOF.
In this study, we selected 71 CHD candidate genes,
based on the evidences of methylation microarray per-
formed previously [24], transcriptional studies, mouse
models and their close association with the heart devel-
opment, to explore their promoter DNA methylation
changes and their association with TOF development.Materials and methods
Patients and controls
The TOF cases were recruited from the Children’s Hospital
of the Fudan University, Shanghai, China. Cardiovascular
diagnosis was obtained by echocardiography. All TOF cases
were tested for chromosome anomalies by karyotype and
22q11 deletion by fluorescent in situ hybridization (FISH)
as previously described [25]. Patients with trisomy 21,
22q11 deletion, other chromosomal anomalies, or extracar-
diac major or minor associated anomalies were discarded
in this study. A total of 41 TOF cases were recruited, in-
cluding 26 (63.4%) males and 15 (36.6%) females, ranging
in age from 2.0 to 48.0 months [11.0 (7.0 - 24.0), median
(interquartile range)].
The control group was comprised of necropsy specimens
from normal subjects that had died as a result of an acci-
dent. Necropsy specimens were collected at the forensic
medicine department of the Fudan University, Shanghai,
China. Considering a delay with necropsy, the post mortem
interval (PMI) for the control samples was as short as pos-
sible. Six age-matched normal controls were collected, in-
cluding 4 (66.7%) males and 2 (33.3%) females, ranging in
age from 6.0 to 54.0 months [15.0 (10.5 - 30.0), median
(interquartile range)]. Anagraphical characteristics of the
study subjects are summarized in Table 1.
To exclude the tissue heterogeneity that may affect
methylation levels, all heart tissue samples from TOF
patients and controls were obtained from the right ven-
tricular myocardial tissues and saved in storage solution
(RNAlater®, AMBION, Inc., Austin, USA) immediately
following surgical resection or necropsy and then stored
in −80°C until use.
The Fudan University’ Ethics Committee approved this
study. Written informed consents were obtained from
the parents or relatives of all study subjects.
DNA extraction and sodium bisulfite conversion
Genomic DNA was extracted from myocardial tissues using
a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. The concen-
tration and purity of the DNA were determined by
absorbance at 260 and 280 nm using a NanoDrop™ 1000
Spectrophotometer (Thermo Scientific, Wilmington,
DE, USA) and agarose gel. Sodium bisulfite modification
Table 2 Information on the promoter region of analyzed
candidate genes
Amplicon Gene
In total 113 71
CpGI 72 50a
CpGI shore 24 23b
no CpG 17 12
Note: aand bhave overlapped genes.
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Methylation Kit™ (Zymo Research, Orange, CA, USA)
strictly following the manufacturer’s instructions. The
bisulfite-converted DNA was re-suspended in 10 μl elu-
tion buffer and stored at −80°C until the samples were
ready for analysis.
MassARRAY quantitative methylation analysis
The Sequenom MassARRAY platform was used to perform
the quantitative methylation analysis for the promoter re-
gions of 71 CHD candidate genes. The methylation status
of a detected pattern was then analyzed using Epityper soft-
ware version 1.0 (Sequenom, San Diego, CA, USA). The
promoter regions of the 71 CHD candidate genes were
chosen using the website http://genome.ucsc.edu (shown in
Additional file 1: Table S1). The 113 amplicons and PCR
primers used in this system were designed using the web-
site http://epidesigner.com (Additional file 1: Table S2).
All experiments were performed as described before
[23]. Non-applicable readings and their corresponding
sites were eliminated from analysis. The methylation
level of the genes promoter regions is expressed as the
percentage of methylated cytosines over the total of
methylated and unmethylated cytosines.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from tested myocardial tissue
samples using Trizol Reagent (Invitrogen, CA, USA) ac-
cording to the manufacturer’s instructions. The extracted
RNA quality and integrity were validated before use. RNA
was reverse-transcribed using a PrimeScript RT reagent Kit
with gDNA Eraser (Perfect Real Time) (TaKaRa, Japan) and
the integrity of synthesized cDNA was confirmed using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as
the endogenous control. Quantitative RT-PCR was per-
formed in a 7900 real-time PCR system using SYBR Premix
Ex Taq GC (Perfect Real Time) (TaKaRa, Japan) following
the manufacturer’s instructions. Reactions were performed
in triplicate and analyzed using an ABI 7900 Sequence De-
tection System (Applied Biosystems, Foster City, CA, USA).
Relative expression levels were calculated according to the
standard 2-ΔΔCt method using beta-2 microglobulin (B2M)
and the GAPDH gene as the endogenous control for
normalization. Primer sequences used in QRT-PCR analysis
are listed in Additional file 1: Table S3.
Statistical analysis
The methylation status of the CHD candidate genes’
promoter regions was analyzed using GraphPad Prism
(version 5.0; GraphPad Software Inc., San Diego, CA,
USA) and SPSS (version 13.0; SPSS Inc., Chicago, IL,
USA). A Mann–Whitney test was used to evaluate the
significance of any differences between TOF cases and
normal controls. Spearman’s rank correlation was usedto examine the relationship between two continuous var-
iables. All statistical analyses were 2-sided and P < 0.05
was considered statistically significant.
Results
Methylation status analyses of the promoter region of 71
CHD candidate genes in TOF cases and controls
To comprehensively understand the promoter regions of
CHD candidate genes that were analyzed, we focused on
the region covering 2000 bp + 200 bases relative to tran-
scription start sites (TSS). Based on the information re-
garding the promoter region in each of 71 candidate
genes, we designed a total of 113 amplicons, of which 72
covered the CpG island (64%), 24 covered the CpG is-
land shore (21%) and 17 were not associated with CpG
island (15%) (shown in Table 2). Using the Sequenom
MassARRAY platform, the methylation levels in the pro-
moter regions of these genes were detected in 10 TOF
cases and 6 controls for the first round of screening.
Prior to analysis, we performed strict quality control to
remove any potentially unreliable measurements, such
as low mass, high mass, and silent peak overlap CpG
units. The CpG units that failed to produce data in more
than 30% of samples (unreliable CpG units) and samples
that were missing more than 30% of the data points (un-
reliable samples) were discarded [26]. The mean and
median methylation levels for the 113 amplicons (71
candidate genes) in the TOF cases and controls are
shown in Additional file 1: Table S4.
The results indicated that the median methylation values
in 26 of 113 amplicons (26 genes) were significantly differ-
ent in TOF cases compared with controls (shown in
Additional file 1: Table S5, p < 0.05). The methylation levels
were up regulated in 17 genes, including CFC1B, DVL2,
EGFR, EDNRA, EVC2, GJA5, HAND1, HAS2, HSPG2,
MED13L, NFATC1, NKX2-5, NFATC2, PAX3, TBX5, TEK
and ZFPM2. Whereas, the methylation levels was down
regulated in 9 genes, including EDN1, HOXA3, MYH6,
NR2F2, NRG1, NRP1, PDGFRA, SLC2A10, and TBX20.
There were 14 amplicons (14 genes: DVL2, EDN1, EGFR,
EVC2, HAND1, HAS2, HSPG2, NKX2-5, NRG1, NFATC2,
PAX3, PDGFRA, SLC2A10, TBX20), located in the CpG
islands; 7 amplicons (7 genes: EDNRA, MED13L, NFATC1,
NR2F2, NRP1, TBX5, ZFPM2), were located in the CpG
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HOXA3, MYH6 ,TEK), covered the region near transcrip-
tion start site (TSS).
Validation of the methylation statuses of seven candidate
genes in TOF cases and controls
On the basis of the data analyzed above, 7 CHD candi-
date genes, including EGFR, EVC2, NFATC2, NR2F2,
TBX5, CFC1B and GJA5, were chosen and validated for
their methylation levels in the samples from 41 patients
with TOF. These genes were selected because they func-
tion as key factors in the development of heart as well as
showing significant differences in methylation status be-
tween TOF cases and controls. Moreover, the amplicon
fragments measured in these genes were distributed
in different regions of the promoter: EGFR, EVC2 and
NFATC2 were associated with the CpG islands, NR2F2
and TBX5 with the CpG island shores and CFC1B and
GJA5 were in the regions near the TSS.
As shown in Table 3, the significant differences for
methylation values of the 7 genes were confirmed in a
larger number of samples. In the CpG island region of
gene promoter in TOF cases, the methylation levels
of the following genes were significantly up-regulated:
EGFR (52.75% vs 60.50%, median, p = 0.0042, Figure 1A),
EVC2 (29.63% vs 43.88%, median, p = 0.0005, Figure 1B),
and NFATC2 (21.80% vs 30.29%, median, p = 0.0067,
Figure 1C). The concurrent higher methylation of EGFR,
EVC2 and NFATC2 might represent a CpG island meth-
ylator phenotype in TOF development.
In the CpG island shore region of gene promoter in
TOF cases, the methylation level of NR2F2 was signifi-
cantly down regulated (62.50% vs 43.40%, median, p =
0.0161, Figure 2A), though the methylation level of
TBX5 was higher (42.04% vs 57.13%, median, p = 0.0207,
Figure 2B) in TOF cases.
Furthermore, in the TSS promoter region of gene in TOF
cases, the methylation levels of CFC1B_M2 and GJA5 were
significantly up regulated (48.16% vs 63.50%, median, p =
0.0178, Figure 2C; 32.83% vs 44.00%, median, p = 0.0138,
Figure 2D; respectively) compared to controls.Table 3 The median methylation values for 7 CHD candidate
and controls
Gene Gene bank accession Gene amplicon Control, med
EGFR NM_201282 EGFR _M1 52.75(44.00-56
EVC2 NM_001166136 EVC2 _M1 29.63(18.84-32
NFATC2 NM_001136021 NFATC2_M2 21.80(17.50-25
NR2F2 NM_021005 NR2F2 62.50(54.35-68
TBX5 NM_080717 TBX5_M1 42.04(32.97-54
CFC1B NM_001079530 CFC1B_M2 48.16(40.36-59
GJA5 NM_005266 GJA5 32.83(29.00-36
*P < 0.05, **P < 0.01, ***P < 0.001 (Mann–Whitney test), IQR, Interquartile range.mRNA expression levels of seven CHD candidate genes in
TOF cases and controls
QRT-PCR was performed to determine the mRNA ex-
pression levels of the 7 CHD candidate genes in TOF
cases and normal controls. As shown in Table 4, the
mRNA levels of the 7 candidate genes were significantly
lower in TOF cases than in controls (p < 0.05).
Correlations between methylation statuses of seven CHD
candidate genes and their respective mRNA levels
A correlation analysis was then done in the TOF cases
to identify whether there was any relationship between
the methylation statuses and mRNA levels of 7 CHD
candidate genes. In the promoter CpG island region,
two significant associations were found between the
methylation statuses and mRNA levels for EGFR (r = −
0.531, p = 0.0015, Figure 3A) and EVC2 (r = − 0.409, p =
0.020, Figure 3B). No significant correlation was observed
between the methylation status and mRNA level for
NFATC2 (r = − 0.212, p = 0.183, Figure 3C).
In the CpG island shore region, no significant correl-
ation was observed between the methylation status and
mRNA level of NR2F2 (r = − 0.074, p = 0.644, Figure 4A).
Interestingly, the methylation status of TBX5 was nega-
tively correlated with its mRNA expression level (r = −
0.418, p = 0.0101, Figure 4B).
A strong correlation was found between the methyla-
tion level in the promoter region near the TSS of CFC1B
and its mRNA level (r = − 0.555, p = 0.0002, Figure 4C).
However, the methylation status of GJA5 was not signifi-
cantly associated with its mRNA level (r = 0.068, p =
0.690, Figure 4D).
Discussion
DNA methylation constitutes an important epigenetic
regulation mechanism in many eukaryotes [27]. In previ-
ous study, we have demonstrated the hypomethylation
of LINE-1, which can serve as an indicator of global
DNA methylation [28], in the myocardial tissue of TOF
patients [23]. In the present study, quantitative methyla-
tion analysis was performed on the promoter region ofgenes showing significant differences between TOF cases
ian (IQR); N TOF, median (IQR); N P value Position
.35);N = 6 60.50(56.10-68.08);N = 33 0.0042** CpGI
.25);N = 6 43.88(36.44-53.28);N = 32 0.0005*** CpGI
.53);N = 6 30.29(26.06-36.57);N = 41 0.0067** CpGI
.30);N = 6 43.40(33.90-53.10);N = 41 0.0161* CpGI shore
.69);N = 6 57.13(50.69-67.31);N = 37 0.0207* CpGI shore
.25);N = 6 63.50(53.57-80.60);N = 39 0.0178* TSS
.08);N = 6 44.00(34.67-53.92);N = 36 0.0138* TSS
Figure 1 Median methylation levels in the promoter CpG islands of candidate genes of TOF cases and controls. (A) EGFR_M1 median
methylation level; (B) EVC2_M1 median methylation level; (C) NFATC2_M2 median methylation level. TSS, Transcription Start Sites; red vertical line,
CpG sites; red thick bars, CpG islands; M, MassARRAY amplicon; The region between two arrows, target amplicon. *P < 0.05, **P < 0.01, ***P < 0.001
(Mann–Whitney test).
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cases and normal controls using the Sequenom MassAR-
RAY platform. This system combines base-specific enzym-
atic cleavage with MALDI-TOF mass spectrometry and
creates a highly accurate, sensitive, and high-throughput
method for the quantitative analysis of DNA methylation at
CpG units [29]. The robustness of this approach forFigure 2 Median methylation levels in the promoter CpG island shore
near the TSS between TOF cases and controls. (A) NR2F2 median meth
methylation level; (D) GJA5 median methylation level; TSS, Transcription
The region between two arrows, target amplicon. *P < 0.05, **P < 0.01, *quantifying methylated and unmethylated DNA has been
confirmed by the Sequenom group [30]. We found that 26
of the 71 candidate genes showed significant differences in
the methylation levels when comparing TOF cases to con-
trols (p < 0.05). In which, 17 genes were up regulation and
9 genes were down regulation. DNA methylation analysis
for multiple genes in TOF cases enables us to reveal thes and the promoter region located outside of the CpG island but
ylation level; (B) TBX5 median methylation level; (C) CFC1B median
Start Sites; red vertical line, CpG sites; red thick bars, CpG islands;
**P < 0.001 (Mann–Whitney test).
Table 4 Median mRNA levels for 7 candidate genes in TOF cases and controls
Gene Gene bank accession Control, median (IQR), N TOF, median (IQR), N mRNA fold change P value
EGFR NM_201282 3.98 (1.84 – 6.93); N = 6 0.61 (0.46 – 0.75); N = 33 0.15 0.0003***
EVC2 NM_001166136 3.95 (1.50 – 6.21); N = 6 0.96 (0.79 – 1.56); N = 32 0.24 0.0033**
NFATC2 NM_001136021 7.72 (4.60 – 11.50); N = 6 1.39 (0.97 – 1.88); N = 41 0.18 0.0043**
NR2F2 NM_021005 3.27 (1.34 – 4.88); N = 6 1.12 (0.70 – 1.30); N = 41 0.34 0.0039**
TBX5 NM_080717 1.49 (1.35 – 4.42);N = 6 0.41 (0.19 – 0.67); N = 37 0.28 0.0013**
CFC1B NM_001079530 2.20 (1.57 – 7.50); N = 6 0.66 (0.31 – 1.07); N = 39 0.30 0.0016**
GJA5 NM_005266 0.77 (0.34 – 1.06); N = 6 0.19 (0.16 – 0.32); N = 36 0.25 0.0053**
**P < 0.01, ***P < 0.001 (Mann–Whitney test), IQR, Interquartile range.
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potential development of new treatments for TOF disease.
The methylation statuses at different regions of the
gene promoter may have different effects on the gene’s
activities. The 26 genes showing significant differences
in the methylation levels can be grouped to three cat-
egories according to the location of amplicons in the
gene promoter. Fourteen amplicons (14 genes) were
located in the CpG islands, 7 amplicons (7 genes) were
located in the CpG island shore, and 5 amplicons (5
genes) were covering the region near the TSS.
Seven CHD candidate genes, including EGFR, EVC2,
NFATC2, NR2F2, TBX5, CFC1B and GJA5, were chosen
for further validation in a larger number of TOF cases
because of their nominally significant differences in
methylation levels and the important roles they play in
the development of the heart. EGFR, a receptor tyrosine
kinase in the ErbB family, activates several signaling cas-
cades that convert extra-cellular cues into appropriate
cellular responses and has been demonstrated to be as-
sociated with the congenital left ventricular outflow tract
obstruction [31]. EVC2 plays a critical role in bone for-
mation and skeletal development and mutations in
EVC2 are associated with Ellis van Creveld syndrome in
which 50-60% of congenital heart defects occur [32].Figure 3 Correlation of methylation status in the promoter CpG islan
EGFR gene; (B) EVC2 gene; (C) NFATC2 gene. *P < 0.05, **P < 0.01, ***P < 0.NFATC2 is a DNA binding protein with a REL-homology
region (RHR) and an NFAT-homology region (NHR). It
plays a central role in inducing gene transcription during
the immune response. Bourajjaj M. et all, 2008, have shown
that NFATC2 is a necessary mediator of calcineurin-
dependent cardiac hypertrophy and heart failure [33].
NR2F2 is a ligand inducible transcription factor that is
involved in the regulation of many different genes and the
deletion of NR2F2 was considered to possibly contribute to
congenital heart defects [34]. TBX5 is a member of the
T-box transcription factor family and plays an important
role in heart development and the specification of limb
identity, which is very well known associated with Holt
Oram syndrome, a developmental disorder affecting the
heart and upper limbs [35]. The regulatory variation in the
TBX5 enhancer can lead to the same phenotype as a muta-
tion in the gene. CFC1B is an important factor in embryo
development. Mutations in this gene have been reported in
Chinese children with congenital heart disease [36]. The
GJA5 gene encodes for the cardiac gap junction protein
connexin 40. A variant in the carboxyl-terminus of con-
nexin 40 alters GAP junctions and increases the risk for
TOF [37].
Aberrant DNA methylation of CpG islands has been
widely observed in human tumors and is associated withds of candidate genes with their mRNA levels in TOF cases. (A)
001. (Spearman’s rank correlation test).
Figure 4 Correlation of methylation status in the promoter CpG island shore and the promoter region near TSS of candidate genes
with their mRNA levels in TOF cases. (A) NR2F2 gene; (B) TBX5 gene; (C) CFC1B gene; (D) GJA5 gene. *P < 0.05, **P < 0.01, ***P < 0.001.
(Spearman’s rank correlation test).
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Multiple genes showing increased or decreased methyla-
tion simultaneously have been found in colorectal cancer
[39] and in duodenal adenocarcinomas [40]. In the
present study, we found significantly higher methylation
levels in the promoter CpG islands of EGFR, EVC2 and
NFATC2 in TOF cases compared with controls. The simul-
taneous higher methylation of EGFR, EVC2 and NFATC2
may represented a CpG island methylator phenotype in
TOF development and provide useful clues as to the devel-
opment of an epigenetic classification of the disease with
prognostic and therapeutic potential. Moreover, EGFR and
EVC2 were found to have significant negative correlations
between methylation values and respective mRNA expres-
sion levels (Figure 3A,B , p < 0.05), indicating that methyla-
tion changes at the CpG island region of the two genes
may have influences on gene expression, though theexact control mechanism requires further study. Al-
though the mRNA level of NFATC2 was significantly
lower in TOF cases compared to the controls in our
study (p < 0.05), no significant correlation between
methylation level and mRNA expression was observed
(Figure 3C, p > 0.05). We concluded that the analyzed
methylation region at the promoter CpG island of
NFATC2 might not be involved in regulating the gene
transcription.
A recent genome-wide analysis of DNA methylation
showed that 76% of differential tissue methylation re-
gions were not located in CpG islands, but in CpG is-
land shore [18]. In this study, we found a decreased
methylation level at the CpG island shore for NR2F2
and an increased methylation level for TBX5. We cannot
ascertain the factor that contributed to the lower methy-
lation level of NR2F2. However, the methylation status
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mRNA level, suggesting that methylation changes at the
CpG island shore of NR2F2 might not influence tran-
scriptional activity. Further studies are needed to explore
whether the methylation changes in the other region of
NR2F2 promoter influences its mRNA level. Interest-
ingly, the methylation status of the TBX5 gene was sig-
nificantly negatively correlated with its mRNA level,
indicating that increased methylation level at the CpG
island shore of TBX5 may inhibit this gene transcrip-
tional activity.
DNA methylation can directly inhibit transcription by
precluding the recruitment of DNA binding proteins
from their target sites [41]. Cao et al. found that CpG
site-specific methylation can alter binding affinities of
specific transcription factors, which can differentially
activate or repress transcription [42]. Consistent with
this, Tihomira D et al. have reported that, although
methylation of all CpG sites resulted in the silencing of
EphA5 promoter activity, lower levels of methylation re-
sulted in differential activation or repression of EphA5
promoter activity, depending on the sites methylated
[43]. In the current study, the methylation levels at the
promoter region near the TSS of CFC1B and GJA5 were
significantly higher in TOF cases compared to normal con-
trols. In addition, other than GJA5, one significant negative
correlation was observed between the methylation status
and mRNA level of CFC1B, indicating that the methylation
change at the promoter region near the TSS of CFC1B may
play an important role in regulating the gene transcriptional
activity. How the altered methylation statuses of CFC1B in-
fluence mRNA level requires further study.
However, in the present study, we have not examined
the protein levels of these genes in the myocardial tissue
because of the limited samples. The potential alterations
of the protein levels and their associations with the tran-
scription level would be explored in the further study.
Conclusions
Our results suggest that multiple gene-specific DNA
methylation changes at the promoter regions occurred
in TOF cases and may be associated with TOF develop-
ment. The concurrent higher methylation of EGFR,
EVC2 and NFATC2 might constitute a CpG island meth-
ylator phenotype for TOF disease and provide useful
cues to understand epigenetic mechanisms in the devel-
opment of TOF. The methylation values of EGFR,
EVC2, TBX5 and CFC1B were significantly correlated
with their respective mRNA levels (p < 0.05), indicating
that aberrant methylation changes of specific genes may
contributes to the development of TOF. Because heart
tissue samples are difficult to collect from healthy con-
trols and TOF patients, one limitation of this study is
that we were unable to obtain enough complete matchedsamples. This could influence the accuracy of the methy-
lation results. Also, we cannot be sure if the methylation
patterns observed in the samples were an effect of or
caused the TOF since the development of TOF long pre-
dated the measurement of methylation. Further studies
with larger sample numbers are warranted to confirm
our findings and to focus on whether aberrant methyla-
tion contributes to TOF development.Additional file
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